Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 3, 2007

AEterna Zentaris Sells Echelon to Frontier Scientific for $3.2M

  • Frontier Scientific bought Echelon Biosciences from AEterna Zentaris in a transaction valued at $3.2 million. This includes $2.6 million payable upfront and a $0.6 million in contingent consideration.

    Frontier Scientific and Echelon focus on a common life science research customer base, which includes pharmaceutical companies and research universities around the world. The firms will maintain their current facilities in Logan and Salt Lake City, both in Utah.

    Frontier Scientific supplies specialized biochemical synthetic organic chemistry. Echelon develops and markets reagents and assays to look inside the human cell at lipids-related signaling mistakes.

    “Frontier Scientific and Echelon Biosciences both have outstanding personnel and complementary markets, technologies, facilities, and operations,” comments Jerry Bommer, president of Frontier Scientific. “The acquisition will lead to new technology development and growth opportunities.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »